/
Other
PARP Inhibitor
4
Pipeline Programs↗
4
Active Trials↗
4
Companies Involved↗
PARP Inhibitor is an early-stage landscape with 4 programs across 4 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
4programs
Small molecule250%
Monoclonal antibody125%
Antibody–drug conjugate125%
Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
12
clinical trials
Completed5 · 42%
Recruiting3 · 25%
Withdrawn2 · 17%
Not yet recruiting1 · 8%
Terminated1 · 8%
Clinical Trials
Trial Activity
12 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)